PTO Form 1581 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 10/31/2017) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
85183667 |
LAW OFFICE ASSIGNED |
LAW OFFICE 114 |
MARK SECTION |
MARK |
TRULICITY |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
TRULICITY |
OWNER SECTION |
NAME |
Eli Lilly and Company |
STREET |
Lilly Corporate Center |
CITY |
Indianapolis |
STATE |
Indiana |
ZIP/POSTAL CODE |
46285 |
COUNTRY |
United States |
PHONE |
317-276-9624 |
FAX |
317-276-1919 |
EMAIL |
XXXX |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, anxiety, bone and skeletal
diseases and disorders, blood disorders, cancer, cardiovascular diseases, cholesterol disorders, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders,
gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders,
neurodegenerative diseases and disorders, neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic
diseases and disorders; antipsychotics; antidepressants; pharmaceutical preparations for use in the treatment of anxiety spectrum disorders, atherosclerosis and Alzheimer's; pharmaceutical
preparations for use in the treatment of diabetes; pharmaceutical preparations for use in the treatment of rheumatoid arthritis; pharmaceutical preparations for use in the treatment of Crohn's
disease, systemic lupus erythematosus, and ankylosing spondylitis disease; pharmaceutical preparations for use in the treatment of psoriasis and psoriatic arthritis; pharmaceutical preparations for
use in the treatment of autoimmune disorders; Veterinary preparations for companion animals in the treatment of weight loss, obesity, urine spraying, chronic pain, gastrointestinal disorders,
neurodegenerative disorders, parasitic infestations, neurological disorders, anxiety, hypertension, dermatitis, cancer, anemia associated with chronic renal failure, fleas, pain associated with
orthopedic and soft tissue surgery, chronic kidney disease, and emesis; preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; veterinary preparations
for the treatment, control and symptomatic relief of infectious and metabolic diseases of livestock; dietary food supplements for animals; antibacterial pharmaceuticals; production enhancement for
livestock, namely, medicated feed and medicated water additives; medicated feed additives and medicated water additives for animals; diagnostic agents, preparations, and substances to identify
pathogens or residues of biological interest for veterinary use |
GOODS OR SERVICES DELETED FROM THE APPLICATION |
anxiety, spectrum, pharmaceutical preparations for use in the treatment of diabetes; pharmaceutical preparations for use in the
treatment of rheumatoid arthritis; pharmaceutical preparations for use in the treatment of Crohn's disease, systemic lupus erythematosus, and ankylosing spondylitis disease; pharmaceutical
preparations for use in the treatment of psoriasis and psoriatic arthritis; |
GOODS OR SERVICES FOR WHICH APPLICANT HAS A CONTINUED BONA FIDE INTENTION, AND IS ENTITLED, TO USE |
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, bone and skeletal diseases and
disorders, blood disorders, cancer, cardiovascular diseases, cholesterol disorders, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders, gastrointestinal
diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases
and disorders, neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders;
antipsychotics; antidepressants; pharmaceutical preparations for use in the treatment of anxiety disorders, atherosclerosis and Alzheimer's; pharmaceutical preparations for use in the treatment of
autoimmune disorders; Veterinary preparations for companion animals in the treatment of weight loss, obesity, urine spraying, chronic pain, gastrointestinal disorders, neurodegenerative disorders,
parasitic infestations, neurological disorders, anxiety, hypertension, dermatitis, cancer, anemia associated with chronic renal failure, fleas, pain associated with orthopedic and soft tissue
surgery, chronic kidney disease, and emesis; preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; veterinary preparations for the treatment, control
and symptomatic relief of infectious and metabolic diseases of livestock; dietary food supplements for animals; antibacterial pharmaceuticals; production enhancement for livestock, namely, medicated
feed and medicated water additives; medicated feed additives and medicated water additives for animals; diagnostic agents, preparations, and substances to identify pathogens or residues of biological
interest for veterinary use |
EXTENSION SECTION |
EXTENSION NUMBER |
2 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
06/07/2011 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT |
150 |
TOTAL AMOUNT |
150 |
SIGNATURE SECTION |
SIGNATURE |
/reljr44/ |
SIGNATORY'S NAME |
Robert E. Lee, Jr. |
SIGNATORY'S POSITION |
Assistant General Patent Counsel |
DATE SIGNED |
04/25/2012 |
SIGNATORY'S PHONE NUMBER |
317 276 9624 |
FILING INFORMATION |
SUBMIT DATE |
Wed Apr 25 18:20:52 EDT 2012 |
TEAS STAMP |
USPTO/ESU-XX.XXX.XX.XX-20
120425182052942409-851836
67-490bded3d245236bcf0dce
cef6276f8d631-DA-9638-201
20425172110109611 |
PTO Form 1581 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 10/31/2017) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: TRULICITY
SERIAL NUMBER: 85183667
The applicant, Eli Lilly and Company, having an address of
Lilly Corporate Center
Indianapolis, Indiana 46285
United States
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 06/07/2011.
For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, anxiety, bone and skeletal diseases and disorders, blood
disorders, cancer, cardiovascular diseases, cholesterol disorders, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders, gastrointestinal diseases and disorders,
hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases and disorders,
neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders; antipsychotics;
antidepressants; pharmaceutical preparations for use in the treatment of anxiety spectrum disorders, atherosclerosis and Alzheimer's; pharmaceutical preparations for use in the treatment of diabetes;
pharmaceutical preparations for use in the treatment of rheumatoid arthritis; pharmaceutical preparations for use in the treatment of Crohn's disease, systemic lupus erythematosus, and ankylosing
spondylitis disease; pharmaceutical preparations for use in the treatment of psoriasis and psoriatic arthritis; pharmaceutical preparations for use in the treatment of autoimmune disorders;
Veterinary preparations for companion animals in the treatment of weight loss, obesity, urine spraying, chronic pain, gastrointestinal disorders, neurodegenerative disorders, parasitic infestations,
neurological disorders, anxiety, hypertension, dermatitis, cancer, anemia associated with chronic renal failure, fleas, pain associated with orthopedic and soft tissue surgery, chronic kidney
disease, and emesis; preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; veterinary preparations for the treatment, control and symptomatic relief
of infectious and metabolic diseases of livestock; dietary food supplements for animals; antibacterial pharmaceuticals; production enhancement for livestock, namely, medicated feed and medicated
water additives; medicated feed additives and medicated water additives for animals; diagnostic agents, preparations, and substances to identify pathogens or residues of biological interest for
veterinary use
This filing does
NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these goods/services are
permanently deleted from this application: anxiety, spectrum, pharmaceutical preparations for use in the treatment of diabetes; pharmaceutical preparations for use in the treatment of rheumatoid
arthritis; pharmaceutical preparations for use in the treatment of Crohn's disease, systemic lupus erythematosus, and ankylosing spondylitis disease; pharmaceutical preparations for use in the
treatment of psoriasis and psoriatic arthritis;
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, bone and skeletal diseases and disorders, blood disorders, cancer,
cardiovascular diseases, cholesterol disorders, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases
and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases and disorders, neurological disorders,
obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders; antipsychotics; antidepressants;
pharmaceutical preparations for use in the treatment of anxiety disorders, atherosclerosis and Alzheimer's; pharmaceutical preparations for use in the treatment of autoimmune disorders; Veterinary
preparations for companion animals in the treatment of weight loss, obesity, urine spraying, chronic pain, gastrointestinal disorders, neurodegenerative disorders, parasitic infestations,
neurological disorders, anxiety, hypertension, dermatitis, cancer, anemia associated with chronic renal failure, fleas, pain associated with orthopedic and soft tissue surgery, chronic kidney
disease, and emesis; preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; veterinary preparations for the treatment, control and symptomatic relief
of infectious and metabolic diseases of livestock; dietary food supplements for animals; antibacterial pharmaceuticals; production enhancement for livestock, namely, medicated feed and medicated
water additives; medicated feed additives and medicated water additives for animals; diagnostic agents, preparations, and substances to identify pathogens or residues of biological interest for
veterinary use
This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.
Declaration
The undersigned, being hereby warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. Section 1001, and that such willful false
statements may jeopardize the validity of the form or any resulting registration, declares that he/she is properly authorized to execute this form on behalf of the applicant; he/she believes the
applicant to be the owner of the trademark/service mark sought to be registered; and that all statements made of his/her own knowledge are true; and that all statements made on information and belief
are believed to be true.
Signature: /reljr44/ Date Signed: 04/25/2012
Signatory's Name: Robert E. Lee, Jr.
Signatory's Position: Assistant General Patent Counsel
Signatory's Phone: 317 276 9624
RAM Sale Number: 9638
RAM Accounting Date: 04/26/2012
Serial Number: 85183667
Internet Transmission Date: Wed Apr 25 18:20:52 EDT 2012
TEAS Stamp: USPTO/ESU-XX.XXX.XX.XX-20120425182052942
409-85183667-490bded3d245236bcf0dcecef62
76f8d631-DA-9638-20120425172110109611